Greater Noida – October 19, 2026 -- YINGFA will present solar cells with measured efficiencies of up to 28.4% at Renewable Energy India Expo 2026, running October 22–24 at India Expo Mart, targeting Indian module manufacturers with cell formats built for varied module designs.

XBC 2.0 cells reach up to 28.4% efficiency with a gridline-free front surface

YINGFA's XBC 2.0 cells combine a pure black appearance with a front surface free of metal gridlines. The company positions them for module designs where both performance and aesthetics matter.

TOPCon 3.0 cells deliver 27.3% in four cut formats

The TOPCon 3.0 line posts a measured cell efficiency of 27.3%. It is available in full-cell, half-cut, third-cut and quarter-cut formats, giving module makers options for different module architectures.

Florence, Italy – October 19, 2026 -- Huawei introduced its upgraded Stellar Intelligent Ultra-Resilient Fabric for the European market at the Huawei Network Summit 2026 Europe (HNS 2026), targeting data center networks that must stay online as scale and complexity grow.

Huawei builds the fabric on StarryWing Digital Map 2.0 and Rock-Solid Architecture 2.0

Johnny Cheng, Vice President of Data Center Network Domain at Huawei Data Communication Product Line, said exponential growth in data center scale and complexity is straining operational efficiency and uptime. Huawei says the solution creates an intelligent, open network fabric that eliminates single points of failure and safeguards critical workloads.

The company cites enhanced intelligence, performance and reliability as the upgrade's core attributes. It pitches the product at enterprises building open data center networks in Europe.

San Diego – October 19, 2026 -- The U.S. Food and Drug Administration's Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) will meet on July 29, 2026, to review Capricor Therapeutics' Biologics License Application (BLA) for Deramiocel, an investigational cell therapy for Duchenne muscular dystrophy (DMD), less than four weeks before the agency's August 22, 2026 PDUFA target action date.

Panel meeting precedes the August 22 PDUFA decision date

Capricor (NASDAQ: CAPR) said its BLA remains on track against the August 22 deadline. The advisory meeting will be livestreamed. The company pointed to the Federal Register and its own website for meeting details.

London – October 19, 2026 -- Transfers under $100 made up 77.4% of stablecoin transfers on BNB Chain in Q3 2026, while transfers of $10,000 or more carried 66.2% of total transfer value, according to a joint report from payments platform Mercuryo and BNB Chain.

The report, Stablecoins on BNB Chain: Fiat to Crypto and Back, combines Mercuryo's fiat-to-crypto and crypto-to-fiat transaction data with BNB Chain's on-chain data for the quarter. The median network fee for a stablecoin transfer on BNB Chain was $0.0068. Additional fees for purchasing, selling or converting into stablecoins may apply.

Non-US currencies fund 70% of dollar-stablecoin purchases through Mercuryo

Of the value used to buy dollar-denominated stablecoins on BNB Chain through Mercuryo, 70% was paid in non-US dollar currencies. The US accounted for 9.8% of purchase value. Asia was the largest regional market at 39.3%, followed by Europe at 33.4%.

San Diego – October 19, 2026 -- Capricor Therapeutics (NASDAQ: CAPR) disputed the post-hoc analyses in the FDA's briefing materials, two days before an advisory committee meets on July 29 to discuss its Biologics License Application (BLA) for Deramiocel, an investigational cell therapy for Duchenne muscular dystrophy (DMD).

Capricor says FDA analyses rely on an obsolete draft analysis plan

The company said the FDA's post-hoc analyses use statistical analysis plan (SAP) version 1.1. Capricor described that version as an unsigned, incomplete internal draft that became obsolete when cohort B was added. It also said the draft lacked content the FDA had specifically requested.

Capricor said its results are governed by SAP version 3.0, which was finalized before unblinding.

San Diego – October 19, 2026 -- Capricor Therapeutics (NASDAQ: CAPR) said The Lancet has published results from its Phase 3 HOPE-3 trial, in which Deramiocel slowed upper limb function decline by 54 percent versus placebo in Duchenne muscular dystrophy (PUL 2.0, p=0.03).

The randomized, double-blind, placebo-controlled trial enrolled 106 participants and met its primary endpoint. Capricor also reports a clinically meaningful cardiac benefit. The results rest on the company's prespecified Statistical Analysis Plan version 3.0 (SAP 3.0).

Miami – October 19, 2026 -- The Global Wellness Summit (GWS) will hold its 20th-anniversary gathering November 10–13 at Angsana Laguna Phuket in Thailand, positioning a $6.8 trillion global wellness economy around the theme "The Science, Art and Soul of Wellness."

The agenda pairs longevity science and medical advances with spirituality, cultural practice and human connection. GWS chief creative officer and executive director Nancy Davis said the industry's scientific progress sits alongside factors such as compassion, purpose and belonging that are harder to quantify.

Thai Schoolgirls to Perform Buddhist Chanting Ceremony

Students from Thailand's Dhammajarinee Witthaya School will perform a traditional Buddhist chanting ceremony. The school serves more than 1,000 underserved girls from across Thailand and has won multiple first-place honors in national Buddhist chanting competitions.

SAN DIEGO – October 19, 2026 -- The FDA's Cellular, Tissue and Gene Therapies Advisory Committee voted 9-3, with no abstentions, that available evidence did not support the effectiveness of Capricor Therapeutics' Deramiocel for cardiomyopathy in patients with Duchenne muscular dystrophy (DMD), leaving the company's PDUFA target action date of August 22, 2026 as the next decision point.

Non-binding vote addresses narrower indication than Capricor proposed

The committee's vote is non-binding. Capricor (NASDAQ: CAPR) said the voting question covered a narrower indication than the one it had proposed and did not include a vote on Deramiocel's overall benefit-risk profile.

Cardiomyopathy in DMD currently has no approved treatment. Capricor said heart muscle deterioration leads to cardiomyopathy and heart failure, the leading cause of death in DMD, which affects approximately 15,000 people in the United States.

Vancouver – October 19, 2026 -- Nevada Organic Phosphate Inc. (CSE: NOP) reported that drill hole MM26-11 intersected 28.7 metres (94.2 feet) of the target Meade Peak Member in northeast Nevada, extending the confirmed strike length of phosphate mineralization to more than 3.3 kilometres.

MM26-11 steps out 315 metres southwest of MM26-10

The hole lies roughly 315 metres (1,037 feet) further southwest along trend from MM26-10. That hole in turn sits 1.5 kilometres (4,921 feet) along strike from MM26-9. Core logging noted oolitic zones typical of the Upper Phosphate Zone. True thickness and phosphate content have not yet been established and await assay.

San Diego – October 19, 2026 -- Capricor Therapeutics (NASDAQ: CAPR) ended the second quarter with about $237.9 million in cash, cash equivalents and marketable securities, down from about $318.1 million at Dec. 31, 2025. The decline came as an FDA advisory committee voted 9 against and 3 in favor on whether evidence shows Deramiocel is effective for cardiomyopathy in Duchenne muscular dystrophy (DMD) patients.

Advisory panel vote is non-binding and limited to cardiomyopathy

The Cellular, Tissue and Gene Therapies Advisory Committee voted on July 29, 2026. Capricor says the panel was not asked to vote on the HOPE-3 primary endpoint or on overall benefit-risk. In a separate discussion of upper limb function, the committee's feedback was directionally supportive of the HOPE-3 evidence, according to the company. The recommendation is advisory and non-binding, and the Biologics License Application (BLA) remains under active FDA review.